# A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

> **NCT00479648** · PHASE2 · COMPLETED · sponsor: **Seqirus** · enrollment: 612 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** CSL412
- **BIOLOGICAL:** Inactivated trivalent influenza vaccine

## Key facts

- **NCT ID:** NCT00479648
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2016-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479648, "A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00479648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*